INT279359

Context Info Confidence 0.20 First Reported 2008 Last Reported 2008 Negated 0 Speculated 0 Reported most in Body Documents 1 Total Number 4 Disease Relevance 2.61 Pain Relevance 1.91

extracellular space (ADA, TNF) plasma membrane (ADA, TNF) small molecule metabolic process (ADA) aging (ADA) intracellular (TNF) extracellular matrix organization (TNF)

ADA (Homo sapiens) TNF (Homo sapiens)

Pain Link Frequency Relevance Heat Adalimumab 844 100.00 Inflammation 44 97.44 cytokine 16 97.28 rheumatoid arthritis 80 95.72 metalloproteinase 4 87.64 Infliximab 260 85.92 Arthritis 12 81.04 spinal inflammation 8 80.16 corticosteroid 80 35.04 methotrexate 28 5.00

Disease Link Frequency Relevance Heat Disease 396 98.60 INFLAMMATION 28 97.44 Rheumatoid Arthritis 80 95.72 Inflammatory Bowel Disease 44 94.40 Serum Sickness 4 88.44 Seronegative Spondarthritis 8 81.84 Low Back Pain 8 80.16 Apoptosis 12 74.16 Adhesions 4 51.80 Fistula 56 30.80

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

First named D2E7, ADA (Humira®; Abbott Laboratories, Abbott Park, IL, USA) is a subcutaneously administered, recombinant, fully human, IgG1 monoclonal antibody that binds with high affinity and specificity to human TNF-alpha, thus modulating its biologic functions (Plosker and Lyseng-Williamson 2007).

ADA Binding (binds) of TNF associated with adalimumab

1) Confidence 0.20 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 0.64 Pain Relevance 0.51

ADA is a recombinant, fully human, IgG1 monoclonal antibody that binds specifically to TNF-alpha, but not lymphotoxin, thereby neutralizing the effect of the cytokine by blocking its interaction with p55 and p75 cell surface TNF receptors (Tracey et al 2008).

ADA Binding (binds) of TNF associated with adalimumab and cytokine

2) Confidence 0.18 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 0.82 Pain Relevance 0.57

Adalimumab (ADA) is a subcutaneously administered, recombinant, fully human, IgG1 monoclonal antibody that binds with high affinity and specificity to human TNF-alpha, thus modulating its biologic functions and its proinflammatory effects.

ADA Binding (binds) of TNF associated with adalimumab

3) Confidence 0.18 Published 2008 Journal Biologics : Targets & Therapy Section Abstract Doc Link PMC2727899 Disease Relevance 0.69 Pain Relevance 0.38

As bivalent monoclonal antibodies, each ADA molecule can bind up to two TNF-alpha molecules simultaneously, whereas a single TNF-alpha homotrimer can bind up to 3 molecules of ADA (Santora et al 2001; Scallon et al 2002).

ADA Binding (bind) of TNF associated with adalimumab

4) Confidence 0.18 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727899 Disease Relevance 0.45 Pain Relevance 0.47

General Comments

This test has worked.